# Validation Study of a Serum-miRNA Signature in Glioma Patients.

> **NCT06178692** · — · UNKNOWN · sponsor: **Regina Elena Cancer Institute** · enrollment: 30 (actual)

## Conditions studied

- Biomarker

## Interventions

- **DIAGNOSTIC_TEST:** Validation of miRNA-serum signatures associated with IDH1 status

## Key facts

- **NCT ID:** NCT06178692
- **Lead sponsor:** Regina Elena Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-10
- **Primary completion:** 2022-11-17
- **Final completion:** 2024-05-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-12-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06178692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06178692, "Validation Study of a Serum-miRNA Signature in Glioma Patients.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06178692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*